Introduction In the last decade, two new radionuclide-based therapies, 223Radichloride and
radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA), have been …

Abstract Background In prostate cancer (PCa), questions remain on indications for prostate-
specific membrane antigen (PSMA) positron emission tomography (PET) imaging and …

Prostate cancer is a major global health care challenge. Due to the recent relevant
improvements in the diagnosis, imaging and treatment, management of these patients is …

Purpose Quantitative prostate-specific membrane antigen (PSMA) PET analysis may
provide for non-invasive and objective risk stratification of primary prostate cancer (PCa) …

The role of molecular imaging using small-molecule ligands labelled with 68Ga or 18F that
bind to prostate-specific membrane antigen (PSMA) continues to be defined for men …

Prostate-specific antigen (PSA) is currently the most widely used biomarker of prostate
cancer (PCa). PSA suggests the presence of primary tumour and disease relapse after …

Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Simple Summary Accurate primary staging for determining the extent of prostate cancer is
crucial for planning treatment in high-risk patients for distant metastases. Recurrence is still …

Prostate cancer (PCa) is one of the most frequently diagnosed malignancies of men in the
world. Due to a variety of treatment options in different risk groups, proper diagnostic and …

Radiolabelled small molecules for imaging prostate cancer have rapidly emerged over the
last few years with gallium-68-labelled prostate-specific-membrane-antigen-11 (68Ga …